@article{c287951cdd5e4d9bb226d27520afc31c,
title = "Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405",
abstract = "Background: In nonmetastatic colorectal cancer, overweight and mild-to-moderately obese patients experience improved outcomes compared with other patients. Obesity's influence on advanced or metastatic colorectal cancer (mCRC) is relatively unexplored. Methods: We conducted a prospective body mass index (BMI) companion study in Cancer and Leukemia Group B (now Alliance)/SWOG 80405, a phase III metastatic colorectal cancer (mCRC) treatment trial. BMI was measured at trial registration. Primary and secondary endpoints were overall and progression-free survival, respectively. To minimize confounding by poor and rapidly declining health, we used Cox proportional hazards regression to adjust for known prognostic factors, comorbidities, physical activity, and weight loss during the 6 months prior to study entry. We also examined weight loss prior to enrollment as an independent predictor of patient outcome. All statistical tests were two-sided. Results: Among 2323 patients with mCRC, there were no statistically significant associations between BMI and overall or progression-free survival (adjusted Ptrend = .12 and .40, respectively). Weight loss during the 6 months prior to study entry was associated with shorter overall and progression-free survival; compared with individuals with stable weight 64.9%, individuals with weight loss greater than 15% experienced an adjusted hazard ratio of 1.52 for all-cause mortality (95% confidence interval [CI] = 1.26 to 1.84; Ptrend < .001) and of 1.23 for disease progression or death (95% CI = 1.02 to 1.47; Ptrend = .006). Conclusions: In this prospective study of patients with mCRC, BMI at time of first-line chemotherapy initiation was not associated with patient outcome. Weight loss prior to study entry was associated with increased risk of patient mortality and disease progression.",
author = "Guercio, {Brendan J.} and Sui Zhang and Venook, {Alan P.} and Ou, {Fang Shu} and Donna Niedzwiecki and Lenz, {Heinz Josef} and Federico Innocenti and Mullen, {Brian C.} and O'Neil, {Bert H.} and Shaw, {James E.} and Polite, {Blase N.} and Hochster, {Howard S.} and Atkins, {James N.} and Goldberg, {Richard M.} and Brown, {Justin C.} and O'Reilly, {Eileen M.} and Mayer, {Robert J.} and Blanke, {Charles D.} and Fuchs, {Charles S.} and Meyerhardt, {Jeffrey A.}",
note = "Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology; U10CA180795, U10CA180826, U10CA180836, U10CA180838, U10CA180867, and UG1CA189858; U10CA180820 to ECOG-ACRIN; U10CA180888 and U10CA180830 to SWOG; R01CA169141 and R01CA118553 to CSF; R00CA218603 and R25CA203650 to JCB; and R01CA149222 to JAM); the National Institute of General Medicine Sciences of the National Institutes of Health (grant number U54GM104940 to JCB); the Guo Shu Shi Fund to JAM; the Karen Guo Colon Cancer Research Fund to JAM; the Stone Research Fund to JAM; the Douglas Gray Woodruff Fund to JAM; the Stand-Up-to-Cancer Colorectal Dream Team Grant to CSF; Eli Lily & Company; Genentech; Pfizer; and Sanofi. Funding Information: Conflicts of interest: BJG has conducted clinical studies with institutional research funding from Bristol-Myers Squibb, Genentech, Eli Lily, Pfizer, and Sanofi. JAM has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to Ignyta and COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. APV has served as an advisor/consultant for Taiho Pharmaceutical, Bayer, Halozyme, and Eisai; and has received institutional research funding from Genentech and Bristol-Myers Squibb; royalties from Now-UptoDate for authoring and maintaining two chapters; and travel, accommodations, or other expenses from Genentech, Roche, Halozyme, and Bayer. HJL has served as an advisor/consultant to Merck Serono, Roche, Bayer, and Pfizer; has received honoraria from Merck Serono, Roche, Bayer, and Boehringer Ingelheim; and travel, accommodations, or other expenses from Merck Serono, Bayer, and Roche. BHO has been employed by Eli Lilly and has served as an advisor/consultant to Bristol-Myers Squibb and Merck. BNP has received research funding from Merck; travel, accommodations, or other expenses from Tapestry Pharmaceuticals; and has other relationships with Gerson Lehrman Group. HSH has served as an advisor/consultant to Bayer, Genentech, Amgen, and Exelixis. RMG has served as an advisor/consultant to Merck, Taiho Pharmaceutical, Merck, and Novartis; received research funding from Bristol-Myers Squibb; received honoraria from Amgen; and received travel, accommodations, or other expenses from Merck and Amgen. EMO has received institutional research funding from Genentech, BMS, Halozyme, Celgene, MabVax Therapeutics, ActaBiologica, AstraZeneca, Silenseed, and Polaris; and has served as an advisor/consultant to CytomX Therapeutics, BioLineRx, Targovax, Ipsen, Celgene, Bayer, Polaris, Sobi, and Merck. CSF has served in a leadership role for CytomX Therapeutics, has stock or other ownership interests in CytomX Therapeutics and Entrinsic Health, and has served as an advisor/consultant to Eli Lilly, Sanofi, Merck, Entrinsic Health, Agios, Merrimack Pharmaceuticals, Taiho Pharmaceutical, Genentech, CytomX Therapeutics, Unum Therapeutics, Bain Capital, Bayer, Gilead Sciences, Dicerna, Five Prime Therapeutics, KEW, Celgene, and Pfizer. The remaining authors declare no potential conflicts of interest. Publisher Copyright: {\textcopyright} 2020 Oxford University Press. All rights reserved.",
year = "2021",
doi = "10.1093/JNCICS/PKAA024",
language = "English (US)",
volume = "4",
journal = "JNCI Cancer Spectrum",
issn = "2515-5091",
publisher = "Oxford University Press",
number = "3",
}